Whole Transcriptome Analysis of Adrenal Glands from Prenatal
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
SHARP1 (BHLHE41) Mouse Monoclonal Antibody [Clone ID: OTI3H4] Product Data
OriGene Technologies, Inc. 9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 [email protected] EU: [email protected] CN: [email protected] Product datasheet for TA806354 SHARP1 (BHLHE41) Mouse Monoclonal Antibody [Clone ID: OTI3H4] Product data: Product Type: Primary Antibodies Clone Name: OTI3H4 Applications: IHC, WB Recommended Dilution: WB 1:2000, IHC 1:150 Reactivity: Human Host: Mouse Isotype: IgG1 Clonality: Monoclonal Immunogen: Human recombinant protein fragment corresponding to amino acids 1-297 of human BHLHE41(NP_110389) produced in E.coli. Formulation: PBS (PH 7.3) containing 1% BSA, 50% glycerol and 0.02% sodium azide. Concentration: 1 mg/ml Purification: Purified from mouse ascites fluids or tissue culture supernatant by affinity chromatography (protein A/G) Conjugation: Unconjugated Storage: Store at -20°C as received. Stability: Stable for 12 months from date of receipt. Predicted Protein Size: 50.3 kDa Gene Name: basic helix-loop-helix family member e41 Database Link: NP_110389 Entrez Gene 79365 Human Q9C0J9 Background: This gene encodes a basic helix-loop-helix protein expressed in various tissues. The encoded protein can interact with ARNTL or compete for E-box binding sites in the promoter of PER1 and repress CLOCK/ARNTL's transactivation of PER1. This gene is believed to be involved in the control of circadian rhythm and cell differentiation. Defects in this gene are associated with the short sleep phenotype. [provided by RefSeq, Feb 2014] This product is to be used for laboratory only. Not for diagnostic or therapeutic use. View online » ©2021 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US 1 / 2 SHARP1 (BHLHE41) Mouse Monoclonal Antibody [Clone ID: OTI3H4] – TA806354 Synonyms: BHLHB3; DEC2; hDEC2; SHARP1 Protein Families: Transcription Factors Protein Pathways: Circadian rhythm - mammal Product images: HEK293T cells were transfected with the pCMV6- ENTRY control (Left lane) or pCMV6-ENTRY BHLHE41 ([RC206882], Right lane) cDNA for 48 hrs and lysed. -
Basic Helix-Loop-Helix Transcription Factors DEC1 and DEC2 Regulate the Paclitaxel-Induced Apoptotic Pathway of MCF-7 Human Breast Cancer Cells
INTERNATIONAL JOURNAL OF MoleCular MEDICine 27: 491-495, 2011 Basic helix-loop-helix transcription factors DEC1 and DEC2 regulate the paclitaxel-induced apoptotic pathway of MCF-7 human breast cancer cells YUNYAN WU1,2, FUYUKI SATO1, UJJAL KUMAR BHAWAL3, TAKESHI KAWAMOTO4, KATSUMI FUJIMOTO4, MITSUHIDE NOSHIRO4, SATOKO MOROHASHI1, YUKIO KATO4 and HIROSHI KIJIMA1 1Department of Pathology and Bioscience, Hirosaki University Graduate School of Medicine, Hirosaki 036-8562, Japan; 2Department of Pathology, College of Basic Medical Sciences, China Medical University, Shenyang 110001, P.R. China; 3Department of Oral and Maxillofacial Surgery and High-Tech Research Center, Kanagawa Dental College, Yokosuka 238-8580; 4Department of Dental and Medical Biochemistry, Hiroshima University Graduate School of Biomedical Science, Hiroshima 734-8553, Japan Received November 17, 2010; Accepted January 10, 2011 DOI: 10.3892/ijmm.2011.617 Abstract. Differentiated embryonic chondrocyte gene Introduction (DEC) 1 (BHLHE40/Stra13/Sharp2) and DEC2 (BHLHE41/ Sharp1) are basic helix-loop-helix (bHLH) transcription Paclitaxel is an anti-tumor drug that is used against a wide factors that are associated with the regulation of apoptosis, cell variety of solid tumors (1,2) and affects the expression of proliferation and circadian rhythms, as well as malignancy Bcl-2, Bcl-xL and phosphorylated-c-Jun NH2-terminal kinase in various cancers. However, the roles of DEC1 and DEC2 (JNK), and the activation of caspases and poly (ADP-ribose) expression in breast cancer are poorly understood. In this polymerase PARP (3-6), resulting in the induction of apop- study, we sought to examine the roles of DEC1 and DEC2 tosis by p53-dependent or -independent mechanisms (7-9). -
Progressive Increase in Mtdna 3243A>G Heteroplasmy Causes Abrupt
Progressive increase in mtDNA 3243A>G PNAS PLUS heteroplasmy causes abrupt transcriptional reprogramming Martin Picarda, Jiangwen Zhangb, Saege Hancockc, Olga Derbenevaa, Ryan Golhard, Pawel Golike, Sean O’Hearnf, Shawn Levyg, Prasanth Potluria, Maria Lvovaa, Antonio Davilaa, Chun Shi Lina, Juan Carlos Perinh, Eric F. Rappaporth, Hakon Hakonarsonc, Ian A. Trouncei, Vincent Procaccioj, and Douglas C. Wallacea,1 aCenter for Mitochondrial and Epigenomic Medicine, Children’s Hospital of Philadelphia and the Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA 19104; bSchool of Biological Sciences, The University of Hong Kong, Hong Kong, People’s Republic of China; cTrovagene, San Diego, CA 92130; dCenter for Applied Genomics, Division of Genetics, Department of Pediatrics, and hNucleic Acid/Protein Research Core Facility, Children’s Hospital of Philadelphia, Philadelphia, PA 19104; eInstitute of Genetics and Biotechnology, Warsaw University, 00-927, Warsaw, Poland; fMorton Mower Central Research Laboratory, Sinai Hospital of Baltimore, Baltimore, MD 21215; gGenomics Sevices Laboratory, HudsonAlpha Institute for Biotechnology, Huntsville, AL 35806; iCentre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, East Melbourne, VIC 3002, Australia; and jDepartment of Biochemistry and Genetics, National Center for Neurodegenerative and Mitochondrial Diseases, Centre Hospitalier Universitaire d’Angers, 49933 Angers, France Contributed by Douglas C. Wallace, August 1, 2014 (sent for review May -
Downregulation of Dipeptidyl Peptidase 4 Accelerates Progression to Castration-Resistant Prostate Cancer Joshua W
Published OnlineFirst September 21, 2018; DOI: 10.1158/0008-5472.CAN-18-0687 Cancer Priority Report Research Downregulation of Dipeptidyl Peptidase 4 Accelerates Progression to Castration-Resistant Prostate Cancer Joshua W. Russo1,CeGao2, Swati S. Bhasin2, Olga S. Voznesensky1, Carla Calagua3, Seiji Arai1,4, Peter S. Nelson5, Bruce Montgomery6, Elahe A. Mostaghel5, Eva Corey6, Mary-Ellen Taplin7, Huihui Ye3, Manoj Bhasin2, and Steven P. Balk1 Abstract The standard treatment for metastatic prostate cancer, cleaves dipeptides from multiple growth factors, resulting in androgen deprivation therapy (ADT), is designed to suppress their increased degradation. DPP4 mRNA and protein were androgen receptor (AR) activity. However, men invariably also decreased in clinical CRPC cases, and inhibition of progress to castration-resistant prostate cancer (CRPC), and DPP4 with sitagliptin enhanced the growth of prostate AR reactivation contributes to progression in most cases. To cancer xenografts following castration. Significantly, DPP4 identify mechanisms that may drive CRPC, we examined a inhibitors are frequently used to treat type 2 diabetes as they VCaP prostate cancer xenograft model as tumors progressed increase insulin secretion. Together, these results implicate from initial androgen sensitivity prior to castration to castra- DPP4 as an AR-regulated tumor suppressor gene whose tion resistance and then on to relapse after combined therapy loss enhances growth factor activity and suggest that treat- with further AR-targeted drugs (abiraterone plus enzaluta- ment with DPP4 inhibitors may accelerate emergence of mide). AR activity persisted in castration-resistant and abir- resistance to ADT. aterone/enzalutamide–resistant xenografts and was associated with increased expression of the AR gene and the AR-V7 splice Significance: These findings identify DPP4 as an AR-stim- variant. -
The Title of the Dissertation
UNIVERSITY OF CALIFORNIA SAN DIEGO Novel network-based integrated analyses of multi-omics data reveal new insights into CD8+ T cell differentiation and mouse embryogenesis A dissertation submitted in partial satisfaction of the requirements for the degree Doctor of Philosophy in Bioinformatics and Systems Biology by Kai Zhang Committee in charge: Professor Wei Wang, Chair Professor Pavel Arkadjevich Pevzner, Co-Chair Professor Vineet Bafna Professor Cornelis Murre Professor Bing Ren 2018 Copyright Kai Zhang, 2018 All rights reserved. The dissertation of Kai Zhang is approved, and it is accept- able in quality and form for publication on microfilm and electronically: Co-Chair Chair University of California San Diego 2018 iii EPIGRAPH The only true wisdom is in knowing you know nothing. —Socrates iv TABLE OF CONTENTS Signature Page ....................................... iii Epigraph ........................................... iv Table of Contents ...................................... v List of Figures ........................................ viii List of Tables ........................................ ix Acknowledgements ..................................... x Vita ............................................. xi Abstract of the Dissertation ................................. xii Chapter 1 General introduction ............................ 1 1.1 The applications of graph theory in bioinformatics ......... 1 1.2 Leveraging graphs to conduct integrated analyses .......... 4 1.3 References .............................. 6 Chapter 2 Systematic -
UNIVERSITY of CALIFORNIA Los Angeles
UNIVERSITY OF CALIFORNIA Los Angeles Circadian Gene Networks In Bone Regeneration A thesis submitted in partial satisfaction of the requirements for the degree Master of Science in Oral Biology by Nathaniel Raphael Hassan 2012 ABSTRACT OF THESIS Circadian Gene Networks In Bone Regeneration By Nathaniel Raphael Hassan Master of Science in Oral Biology University of California, Los Angeles, 2012 Professor Ichiro Nishimura, Chair BACKGROUND: Previous studies suggested that vitamin D played a significant role in bone regeneration, facilitating the establishment of implant osseointegration. A whole genome microarray study further suggested that the vitamin D axis might involve circadian rhythm gene expression in the bone peripheral tissue. OBJECTIVES: To identify key gene networks involved with vitamin D receptor in the bone regeneration process and to explore any correlation with circadian rhythm gene expression in bone marrow mesenchymal stromal/stem cells (BMSC). METHODS: The available whole gene microarray data was analyzed using the weighted gene correlation network analysis (WGCNA) R package and Cytoscape software. Any gene expression correlation was examined for vitamin D receptor (VDR) as well as circadian rhythm ii genes. Separately, Per 1 luciferase transgenic Wistar rats were then applied for in vitro evaluation on BMSC circadian rhythm. Per1::luc BMSCs were seeded on 35mm dishes and forskolin-synchronized luminescence was recorded across different media conditions. The recording media included growth medium containing F12 (10% Fetal Bovine Serum, 1% Pen- Strep and antibiotic) supplemented with or without 1 nM 1,25D. Luminescence was also recorded in F12 growth medium containing bone differentiation factors (beta glycerophosphate, Ascorbic acid and Dexamethasone) supplemented with 0, 1 or 10 nM 1,25D. -
NPAS2 As a Transcriptional Regulator of Non-Rapid Eye Movement Sleep: Genotype and Sex Interactions
NPAS2 as a transcriptional regulator of non-rapid eye movement sleep: Genotype and sex interactions Paul Franken*†‡, Carol A. Dudley§, Sandi Jo Estill§, Monique Barakat*, Ryan Thomason¶, Bruce F. O’Hara¶, and Steven L. McKnight‡§ §Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas, TX 75390; *Department of Biological Sciences, Stanford University, Stanford, CA 94305; ¶Department of Biology, University of Kentucky, Lexington, KY 40506; and †Center for Integrative Genomics, University of Lausanne, CH-1015 Lausanne-Dorigny, Switzerland Contributed by Steven L. McKnight, March 13, 2006 Because the transcription factor neuronal Per-Arnt-Sim-type sig- delta frequency range is a sensitive marker of time spent awake (4, nal-sensor protein-domain protein 2 (NPAS2) acts both as a sensor 7) and local cortical activation (8) and is therefore widely used as and an effector of intracellular energy balance, and because sleep an index of NREMS need and intensity. is thought to correct an energy imbalance incurred during waking, The PAS-domain proteins, CLOCK, BMAL1, PERIOD-1 we examined NPAS2’s role in sleep homeostasis using npas2 (PER1), and PER2, play crucial roles in circadian rhythm gener- knockout (npas2؊/؊) mice. We found that, under conditions of ation (9). The NPAS2 paralog CLOCK, like NPAS2, can induce the increased sleep need, i.e., at the end of the active period or after transcription of per1, per2, cryptochrome-1 (cry1), and cry2. PER and sleep deprivation (SD), NPAS2 allows for sleep to occur at times CRY proteins, in turn, inhibit CLOCK- and NPAS2-induced when mice are normally awake. Lack of npas2 affected electroen- transcription, thereby closing a negative-feedback loop that is cephalogram activity of thalamocortical origin; during non-rapid thought to underlie circadian rhythm generation. -
Pharmacological Inhibition of Tumor Anabolism and Host Catabolism As A
www.nature.com/scientificreports OPEN Pharmacological inhibition of tumor anabolism and host catabolism as a cancer therapy Alejandro Schcolnik‑Cabrera1,2, Alma Chavez‑Blanco1, Guadalupe Dominguez‑Gomez1, Mandy Juarez1, Ariana Vargas‑Castillo3, Rafael Isaac Ponce‑Toledo4, Donna Lai5, Sheng Hua5, Armando R. Tovar3, Nimbe Torres3, Delia Perez‑Montiel6, Jose Diaz‑Chavez1 & Alfonso Duenas‑Gonzalez1,7* The malignant energetic demands are satisfed through glycolysis, glutaminolysis and de novo synthesis of fatty acids, while the host curses with a state of catabolism and systemic infammation. The concurrent inhibition of both, tumor anabolism and host catabolism, and their efect upon tumor growth and whole animal metabolism, have not been evaluated. We aimed to evaluate in colon cancer cells a combination of six agents directed to block the tumor anabolism (orlistat + lonidamine + DON) and the host catabolism (growth hormone + insulin + indomethacin). Treatment reduced cellular viability, clonogenic capacity and cell cycle progression. These efects were associated with decreased glycolysis and oxidative phosphorylation, leading to a quiescent energetic phenotype, and with an aberrant transcriptomic landscape showing dysregulation in multiple metabolic pathways. The in vivo evaluation revealed a signifcant tumor volume inhibition, without damage to normal tissues. The six‑drug combination preserved lean tissue and decreased fat loss, while the energy expenditure got decreased. Finally, a reduction in gene expression associated with thermogenesis was observed. Our fndings demonstrate that the simultaneous use of this six‑drug combination has anticancer efects by inducing a quiescent energetic phenotype of cultured cancer cells. Besides, the treatment is well‑ tolerated in mice and reduces whole animal energetic expenditure and fat loss. -
Reconstructing Cell Cycle Pseudo Time-Series Via Single-Cell Transcriptome Data—Supplement
School of Natural Sciences and Mathematics Reconstructing Cell Cycle Pseudo Time-Series Via Single-Cell Transcriptome Data—Supplement UT Dallas Author(s): Michael Q. Zhang Rights: CC BY 4.0 (Attribution) ©2017 The Authors Citation: Liu, Zehua, Huazhe Lou, Kaikun Xie, Hao Wang, et al. 2017. "Reconstructing cell cycle pseudo time-series via single-cell transcriptome data." Nature Communications 8, doi:10.1038/s41467-017-00039-z This document is being made freely available by the Eugene McDermott Library of the University of Texas at Dallas with permission of the copyright owner. All rights are reserved under United States copyright law unless specified otherwise. File name: Supplementary Information Description: Supplementary figures, supplementary tables, supplementary notes, supplementary methods and supplementary references. CCNE1 CCNE1 CCNE1 CCNE1 36 40 32 34 32 35 30 32 28 30 30 28 28 26 24 25 Normalized Expression Normalized Expression Normalized Expression Normalized Expression 26 G1 S G2/M G1 S G2/M G1 S G2/M G1 S G2/M Cell Cycle Stage Cell Cycle Stage Cell Cycle Stage Cell Cycle Stage CCNE1 CCNE1 CCNE1 CCNE1 40 32 40 40 35 30 38 30 30 28 36 25 26 20 20 34 Normalized Expression Normalized Expression Normalized Expression 24 Normalized Expression G1 S G2/M G1 S G2/M G1 S G2/M G1 S G2/M Cell Cycle Stage Cell Cycle Stage Cell Cycle Stage Cell Cycle Stage Supplementary Figure 1 | High stochasticity of single-cell gene expression means, as demonstrated by relative expression levels of gene Ccne1 using the mESC-SMARTer data. For every panel, 20 sample cells were randomly selected for each of the three stages, followed by plotting the mean expression levels at each stage. -
Robert Shine, Peter Dwyer, Lyndsay Olson, Jennifer Truong, Matthew Goddeeris, Effie Tozzo, Eric Bell Mitobridge, Inc
Poster Title Here Mitochondrial Deficiency in Primary Muscle Cells from Mdx Mice Robert Shine, Peter Dwyer, Lyndsay Olson, Jennifer Truong, Matthew Goddeeris, Effie Tozzo, Eric Bell Mitobridge, Inc. Cambridge, MA 02138 Abstract Results Results Duchenne muscular dystrophy (DMD) is a recessive, fatal X-linked disease that is characterized M ito c h o n d ria l c o n trib u te d A T P is re d u c e d Mdx myoblasts have decreased expression by progressive skeletal muscle wasting due to a loss of function in dystrophin, a protein that is of OXPHOS complexes part of a complex that bridges the cytoskeleton and extracellular matrix. The mdx mouse, an in m d x m y o b la s ts a n d m y o tu b e s T animal model for DMD, has a point mutation in the dystrophin gene that results in a loss of 1 .5 2.0 W l function. This study uses primary muscle satellite cell derived myoblasts and myotubes to W T a WT m determine differences in mitochondrial biology between the mdx mice and wild type (WT) control s M D X o 1.5 a r MDX mice. Compared to cells isolated from WT mice, mdx cells have reductions in mitochondrial 1 .0 **** f B bioenergetics. Moreover, mdx cells have reduced levels of mitochondria which may partially *** e T g 1.0 explain the reduction in bioenergetics. Interestingly, the mitochondrial phenotype is apparent **** ** n * * W a * * * before dystrophin protein is increased during myogenesis. * * * 0 .5 h 0.5 * d l C o d l F 0.0 o 1 3 2 6 1 a 1 a b B 0 .0 F t v Materials and Analysis a 5 P X D C H H y 5 l l F X T N R O D a M in a M in D C s s P n n U A c c O S C C a 0 a 0 S y y T B 0 B 0 D WT and mdx myoblast isolation and culture: Quadricep and gastrocnemius muscles from a C 1 m 1 m Q A o o N single mouse were pooled and subjected to a mechanical/collagenase digestion. -
Play Clock Operator Guide
NFHS GENERAL INSTRUCTIONS FOR FOOTBALL GAME AND PLAY CLOCK OPERATORS A. The game and play clock operators should report to the game officials at the stadium at least 30 minutes before game time for the following purposes: 1. To synchronize timer’s watch with official game time as established by the game official responsible for timing. 2. To advise game officials whether the game clock operator and/or play clock operator will be in the press box or on the field/side- line. Determine procedure for communications with both operators and test procedures prior to the games. 3. To discuss coordination of starting, stopping and adjusting the game clock or play clock in accordance with the playing rules. 4. To discuss if the game clock horn (mechanical signal) can be turned off. Preference is for the game clock horn (mechanical signal) to be turned off for the duration of the game. B. The game clock is normally started 30 minutes before game time. The halftime intermission will start on the referee’s signal when the players and game officials leave the field. All pregame and halftime activities shall be synchronized with the game clock. The mandatory three-minute warm-up period will be put on the game clock after the intermission time has elapsed and shall be started immediately. C. The game clock operator shall have an extra stopwatch available. In case of failure of the game clock, the game clock operator shall immediately contact the game officials, giving them the correct data regarding the official time. The game official responsible for timing will then pick up the correct game time on the stopwatch. -
Agonists and Knockdown of Estrogen Receptor Β Differentially Affect
Schüler-Toprak et al. BMC Cancer (2016) 16:951 DOI 10.1186/s12885-016-2973-y RESEARCH ARTICLE Open Access Agonists and knockdown of estrogen receptor β differentially affect invasion of triple-negative breast cancer cells in vitro Susanne Schüler-Toprak1*, Julia Häring1, Elisabeth C. Inwald1, Christoph Moehle2, Olaf Ortmann1 and Oliver Treeck1 Abstract Background: Estrogen receptor β (ERβ) is expressed in the majority of invasive breast cancer cases, irrespective of their subtype, including triple-negative breast cancer (TNBC). Thus, ERβ might be a potential target for therapy of this challenging cancer type. In this in vitro study, we examined the role of ERβ in invasion of two triple-negative breast cancer cell lines. Methods: MDA-MB-231 and HS578T breast cancer cells were treated with the specific ERβ agonists ERB-041, WAY200070, Liquiritigenin and 3β-Adiol. Knockdown of ERβ expression was performed by means of siRNA transfection. Effects on cellular invasion were assessed in vitro by means of a modified Boyden chamber assay. Transcriptome analyses were performed using Affymetrix Human Gene 1.0 ST microarrays. Pathway and gene network analyses were performed by means of Genomatix and Ingenuity Pathway Analysis software. Results: Invasiveness of MBA-MB-231 and HS578T breast cancer cells decreased after treatment with ERβ agonists ERB-041 and WAY200070. Agonists Liquiritigenin and 3β-Adiol only reduced invasion of MDA-MB-231 cells. Knockdown of ERβ expression increased invasiveness of MDA-MB-231 cells about 3-fold. Transcriptome and pathway analyses revealed that ERβ knockdown led to activation of TGFβ signalling and induced expression of a network of genes with functions in extracellular matrix, tumor cell invasion and vitamin D3 metabolism.